The FDA has approved the second biosimilar insulin glargine rival to Lantus, in the form of Eli Lilly’s Rezvoglar. However, Viatris’ recently relaunched Semglee version has an interchangeability designation on its side.
A second biosimilar rival to Sanofi’s Lantus (insulin glargine) has been approved by the US Food and Drug Administration in the form of Eli Lilly’s Rezvoglar (insulin glargine-aglr) 3ml pre-filled pens.
While Lilly has not so far commented on launch plans for the long-acting human insulin analog, the product’s approval comes shortly after Viatris gained approval for and began rolling out the
As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.
With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.
